Interferon-Induced Obsessive-Compulsive Symptoms in Malignant Melanoma

Abstract

Immunotherapy with alpha-interferon (IFN-α) is currently used as adjuvant treatment in patients with malignant melanoma. Psychiatric side effects such depression, mania or psychosis during treatment with IFN-α have been well documented in the literature. In comparison, however, data on interferon-induced obsessive-compulsive disorder are rare. We report here the case of a 23-year-old woman who developed obsessive-compulsive symptoms for the first time during interferon therapy after excision of a malignant melanoma.

Key words

interferon · obsessive-compulsive disorder · malignant melanoma

• References

• 1 Garbe C, Peris K, Hauschild A et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46: 270-283
• 2 Algazi AP, Soon CW, Daud AL. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010; 2: 197-211
• 3 Treisman J, Garlie N. Systemic therapy for cutaneous melanoma. Clin Plast Surg 2010; 37: 127-146
• 4 Schaefer M, Schmidt F, Horn M et al. Depression during treatment with Interferon alpha. Psychosomatics 2004; 45: 176
• 5 Bannink M, Kruit WH, Van Gool AR et al. Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics 2008; 49: 56-63
• 6 Bonaccorso S, Marino V, Puzella A et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immuntherapy are related Interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86-90
• 7 Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000
• 8 Mavrogiorgou P, Gohle D, Winter C et al. Low serotonergic function and its normalization by treatment with sertraline in obsessive-compulsive disorder  −  an auditory evoked potential study. J Clin Psychopharmacology 2010; 30: 341-343
• 9 DeRosse P, Szeszko PR, Malhotra AK. Interferon-induced obsessive-compulsive disorder. Gen Hosp Psychiatry 2006; 28: 357-358
• 10 Navines R, Gomez-Gil E, Puig S et al. Depression in hospitazed patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders. Eur J Dermatol 2009; 19: 611-615
• 11 Heinze S, Egberts F, Rötzer S et al. Depressive mood changes and psychiatric symptoms during 12-month low-dose Interferon-a treatment in patients with malignant melanoma. J Immunother 2010; 33: 106-114
• 12 Capuron L, Gumnick JF, Musselman DL et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symtom dimensions. Neuropsychopharmacology 2002; 26: 643-652
• 13 Kirkwood J, Bender C, Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20: 3703-3718
• 14 Friebe A, Horn M, Schmidt F et al. Dose-dependent development of depressive symptoms during adjuvant interferon {alpha} treatment of patients with malignant melanoma. Psychosoamtics 2010; 51: 466-473
• 15 Yaryura-Tobias JA, Neziroglu F. Biobehavioral Treatment of Obsessive-Compulsive Spectrum Disorders. New York, London: W.W:Norton and Co; 1997
• 16 Goodman WK, Lydiard RB. Recognition and treatment of obsessive-compulsive disorder. J Clin Psychiatry 2007; 68: e30
• 17 Van Gool AR, Van Ojik HH, Kruit WH et al. Pegylated interferon-alpha 2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic and pteridine plasma concentrations. Anticancer Drugs 2004; 15: 587-591
• 18 Schaefer M, Schwaiger M, Pich M et al. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 2003; 36: 203-206